Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Buy dildos.
Popular Articles

Family Drug Support's 'Stepping Stones To Success' Wins At The 2009 National Drug And Alcohol Awards
Family Drug Support"s Stepping Stones to Success program has won the 2009 National Drug and Alcohol Award for Excellence in Prevention and Community Education.
pharmacy online
PET Can Help Guide Treatment Decisions For A Common Pediatric Cancer
A new study published in the August issue of The Journal of Nuclear Medicine shows that positron emission tomography (PET) is an important tool for depicting the extent of neuroblastoma in some patients, particularly for those in the early stages of the disease. Neuroblastoma accounts for six to ten percent of all childhood cancers in the United States and 15 percent of cancer deaths in children. Accurately identifying where in the body the disease is located and whether it is spreading is critical for choosing appropriate types of treatment, which can include surgery, chemotherapy, radiation and-in the most advanced cases-a combination of all of these treatments along with bone marrow transplant or investigational therapies.
News of the day
Doctors Call For Minimum Alcohol Pricing - British Medical Association
Doctors yesterday reaffirmed their support for a minimum pricing strategy for a unit of alcohol. Speaking today at the BMA"s annual conference in Liverpool, Newry consultant and BMA Board of Science member Dr Peter Maguire said,
Mental Health

InDex Pharmaceuticals AB Engages PharmaVentures To Facilitate The Licensing Of Kappaproct(R) After Phase IIa Trial Achieves Clinical Endpoints Early

PharmaVentures Ltd, announced that it has been engaged by InDex Pharmaceuticals AB to advise and assist in out-licensing its first in class therapeutic, Kappaproct (DIMS 0150), for the treatment of steroid resistant / dependent Inflammatory Bowel Disease (IBD). The engagement will utilise PharmaVentures" transactions experience in the healthcare and investment business sectors. Kappaproct, approved for Orphan Drug Designation in Europe, has recently successfully concluded its third clinical phase II trial for the treatment of Inflammatory Bowel Disease patients. Due to the highly positive interim results at both one and four weeks after dosing, this trial, which included 34 patients and was conducted as a multi-center study in Sweden and Russia, was concluded early. Kappaproct showed the same excellent safety profile as seen in previous trials. Kappaproct is currently approved for clinical developmental use as a rectal, single-dose administration. Qualification of the compound for other routes of administration and multiple dosing is underway through an extended toxicology program. Dr Fintan Walton, CEO, PharmaVentures commented, "PharmaVentures is very pleased to be involved in bringing this groundbreaking technology to the market. InDex are leaders in the field of immunomodulation via Toll Like Receptors." A leading results driven organisation, PharmaVentures assists pharmaceutical and biotechnology companies across the world in all aspects of deal making. The Company"s core business is the provision of tailored consulting and transaction advisory services to the Life Science industry, with additional deal making support provided through the PharmaDeals range of intelligence products which include analysis tools and reports. InDex Pharmaceuticals AB ("InDex") is a clinical stage biopharmaceutical company building a leading immunotherapy franchise based on its DIMS platform (DNA-based immunomodulatory sequence). DIMS drugs are developed to treat diseases within a variety of therapeutic areas, including inflammation and cancer. InDex has several proprietary DIMS compounds in various stages of development, including Kappaproct, for the treatment of steroid resistant/dependent ulcerative colitis. PharmaVentures


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009